By: Amanda Kastel, PharmD Candidate c\/o 2027<\/p>\n\n\n\n
On December 22, 2025, the FDA approved the once-daily oral Wegovy\u00ae (semaglutide) tablet, making it the first oral GLP-1 receptor agonist approved for weight management. Although Rybelsus\u00ae (semaglutide) has been available as an oral GLP-1 tablet since 2019, its FDA-approved indication is limited to the treatment of type 2 diabetes mellitus, and it does not carry an indication for weight loss. This approval is a significant advancement in obesity treatment, as it expands access to highly effective GLP-1 therapy for patients who are unwilling or unable to use injectable semaglutide- or tirzepatide-based therapies.<\/p>\n\n\n\n
Approved Indications<\/strong><\/p>\n\n\n\n The Wegovy\u00ae tablet is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity.1<\/sup> It is indicated for:<\/p>\n\n\n\n 1. Chronic weight management in adults with obesity (BMI \u2265 30kg\/m2<\/sup>) or those who are overweight (BMI \u2265 25kg\/m2<\/sup>) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.1<\/sup><\/p>\n\n\n\n 2. To decrease the risk of major cardiovascular events (MACE), such as nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death in patients with established cardiovascular disease who are also obese or overweight.1<\/sup><\/p>\n\n\n\n A key difference in indications between injectable Wegovy\u00ae and oral Wegovy\u00ae is that the oral formulation is not currently approved for use in pediatric patients aged 12 years and older, whereas the injectable formulation carries this indication.1<\/sup><\/p>\n\n\n\n The OASIS 4 Trial<\/strong><\/p>\n\n\n\n The OASIS 4 trial2<\/sup> was a 71-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of oral semaglutide in adults with obesity (BMI \u2265 30 kg\/m\u00b2) or overweight (BMI \u2265 27 kg\/m\u00b2) with at least one weight-related comorbidity. A total of 307 participants were randomized to receive either oral semaglutide 25 mg once daily or placebo, with both groups participating in structured lifestyle interventions.<\/p>\n\n\n\n Participants receiving oral semaglutide were significantly more likely to achieve clinically meaningful weight reductions of at least 5%, 10%, 15%, and 20% compared with placebo (P < 0.001 for all comparisons). Mean body weight reduction from baseline to week 64 was \u221213.6% in the oral semaglutide group compared with \u22122.2% in the placebo group (95% confidence interval, \u221213.9 to \u22129.0; P < 0.001), demonstrating statistically significant and clinically meaningful efficacy in weight management.<\/p>\n\n\n\n Considerations for Pharmacists<\/strong><\/p>\n\n\n\n While the oral formulation of Wegovy\u00ae may be more appealing to some patients, there are several concerns regarding adherence, adverse effects, and access.<\/p>\n\n\n\n Unlike the once-weekly subcutaneous formulation, oral Wegovy\u00ae must be taken daily in the morning on an empty stomach with no more than 4 ounces of plain water.1 <\/sup>Due to extensive first-pass metabolism, oral semaglutide is administered at substantially higher doses than its injectable counterpart. While injectable semaglutide is titrated from 0.25 mg to a maximum of 2.4 mg once weekly, oral Wegovy\u00ae is initiated at 1.5 mg daily and titrated to a maintenance dose of 25 mg daily. Additionally, patients must wait at least 30 minutes before consuming food, beverages, or other medications to optimize absorption in the acidic gastric environment.1<\/sup> These strict administration requirements may pose adherence challenges for some patients, potentially compromising efficacy. In contrast, the injectable formulation is administered weekly without regard to meals, which may improve convenience and adherence.<\/p>\n\n\n\n Like the injection, the oral formulation is associated with a predominantly gastrointestinal side effect profile. In the OASIS 4 trial2<\/sup>, gastrointestinal adverse events such as nausea, vomiting, diarrhea, and abdominal pain were more common in the oral semaglutide group than in the placebo group (74.0% vs. 42.2%).<\/p>\n\n\n\n As of February 2026, access to oral Wegovy\u00ae remains a significant challenge, as many insurers have either not added the medication to their formularies or require prior authorization before coverage. Additionally, barriers such as step therapy and quantity limits are likely to persist, despite overwhelming evidence of the efficacy of GLP-1 medications, including oral Wegovy\u00ae. 1,3<\/sup> Pharmacists play a critical role in navigating these barriers by assisting with prior authorizations, counseling patients on coverage limitations, and suggesting alternative options when patient access is restricted.<\/p>\n\n\n\n REFERENCES<\/p>\n\n\n\n By: Amanda Kastel, PharmD Candidate c\/o 2027 On December 22, 2025, the FDA approved the once-daily oral Wegovy\u00ae (semaglutide) tablet, making it the first oral GLP-1 receptor agonist approved for weight management. Although Rybelsus\u00ae (semaglutide) has been available as an oral GLP-1 tablet since 2019, its FDA-approved indication is limited to the treatment of type…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-4210","post","type-post","status-publish","format-standard","hentry","category-news-politics"],"views":39,"_links":{"self":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/comments?post=4210"}],"version-history":[{"count":1,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4210\/revisions"}],"predecessor-version":[{"id":4211,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4210\/revisions\/4211"}],"wp:attachment":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/media?parent=4210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/categories?post=4210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/tags?post=4210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n